Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma)~* At least one measurable lesion~* No prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma (second line)~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Archived tissue sample or new biopsy sample~* Female participants of childbearing potential must agree to use effective contraception from Visit 1 to 120 days after the last dose of study drug; male participants must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug~Exclusion criteria:~* Prior treatment with ipilimumab or other anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) agent or any anti-programmed cell death (PD-1 or PD-L2) agent~* Chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the first dose of study drug, or not recovered from adverse events caused by cancer therapeutics administered more than four weeks earlier~* Currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study drug~* Expected to require any other form of systemic or localized antineoplastic therapy while on study~* On any systemic steroid therapy within one week before the planned date for first dose of randomized treatment or on any other form of immunosuppressive medication~* History of a malignancy (other than the disease under treatment in the study) within 5 years prior to first study drug administration, excluding adequately treated Stage 1 or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other in situ cancers.~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; participants with previously treated brain metastases are eligible~* Severe hypersensitivity reaction to treatment with another monoclonal antibody~* Active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents~* Active infection requiring systemic therapy~* Known history of Human Immunodeficiency Virus (HIV)~* Known history of or positive for Hepatitis B or C~* Known psychiatric or substance abuse disorder~* Regular user (including recreational use) of illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)~* Pregnant or breastfeeding, or expecting to conceive, or father children within the projected duration of the study~* Received a live vaccine within 30 days prior to first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: EXPERIMENTAL): Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
- Pembrolizumab Q2W (Type: EXPERIMENTAL): Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
- Pembrolizumab Q3W (Type: ACTIVE_COMPARATOR): Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).